The involvement of a chemokine receptor antagonist CTCE-9908 and kynurenine metabolites in cancer development

Abstract

Cancer is the second leading cause of mortality worldwide. Skin cancer is the most common cancer in South Africa with nearly 20,000 reported cases every year and 700 deaths. If diagnosed early, the 5‐year survival rate is about 90%, however, when diagnosed late, the 5‐year survival rate decreases to about 20%. Melanoma is a type of skin cancer with an estimated 5‐year survival rate of approximately 90%. Neuroblastoma is a paediatric cancer with a low survival rate. Sixty percent of patients with metastatic disease do not survive 5 years after diagnosis. Despite recent advances in targeted therapies, there is a crucial need to identify reliable prognostic biomarkers which will be able to contribute to the development of more precision‐based chemotherapeutic strategies to prevent tumour migration and metastasis. The compound, CTCE‐9908 inhibits the binding of CXC chemokine ligand 12 (CXCL12) to the CXC chemokine receptor 4 (CXCR4) receptor leading to reduced metastasis. Kynurenine metabolites are derived tryptophan, which is an essential amino acid. Kynurenine metabolites inhibit T‐cell proliferation resulting in cell growth arrest. For this reason, chemokines receptors represent potential targets for the treatment of cancer growth and metastasis. In this review paper, the role of the CXCL12/CXCR4 signalling pathway in the development of cancer is highlighted together with the current available treatments involving the CTCE‐9908 compound in combination with microtubule inhibitors like paclitaxel and docetaxel.